News/Blog
Read about our latest news:
ENB Therapeutics Closes Series A Round of Funding
New York, NY, September 20, 2018: ENB Therapeutics Inc., a biopharmaceutical company pioneering pathways in endothelin-based oncologics, today announced that it has closed its Series A private equity financing. Proceeds from the financing will be used to advance the...
ENB to present at 2016 Pitch Fest organized by New York Bio
ENB was selected as one of 33 companies to present at this year's Pitch Fest on May 11th, at the New York Bio Annual Conference. The conference is being held at NYC's Time Warner Center. Representative entrepreneurs will give a 15-minute pitch to a panel of judges...
ENB CSO and Co-founder Dr. Sumayah Jamal wins Best-in-show at 1st Pitch Life Science NYC
April, 2016 1st Pitch Life Science is organized by MABA (Mid Atlantic Bio Angels (www.bioangels.net), a life science investor group, to encourage and educate aspiring life science entrepreneurs who want the opportunity to practice their pitch and to receive...
ENB Therapeutics accepted for presentation at the 2016 HemOnc Today Melanoma Conference in NYC
March, 2016 ENB Therapeutics presents poster entitled "Development of ENB-001 for the Treatment of Melanoma Brain Metastasis" at the 2016 HemOnc Today Melanoma and Cutaneous Malignancies Meeting in NYC. The meeting draws more than 250 colleagues and renowned speakers...
ENB’s Co-founder and CSO Dr. Sumayah Jamal is accepted into the 2016 Pharma Class of Springboard Health Innovation Hub
March 2016 Sumayah Jamal, MD-PhD, Co-founder and CSO of ENB was accepted into the 2016 Pharma Class of the Springboard Health Innovation Hub. Springboard’s highly competitive Health Innovation Hub is a year-long program for women-led healthcare and life science...
ENB Lead Product ENB001 Awarded Orphan Drug Designation by the FDA
January 21,2016- FDA awards ENB lead product ENB001 Orphan Drug Designation for Stage IIB- Stage IV melanoma. This represents a major milestone in our development program for ENB001 which now qualifies for various development incentives including tax credits for...
ENB is invited to give a presentation at the 2016 Biotech Showcase
December, 2015. Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during...
Life Sciences Summit 2016 invites ENB to be a pipeline cafe participant
November, 2015 The Life Sciences Summit is an early stage investor and business development conference that highlights innovation. The pipeline café features academic innovators who are hand selected to present their discoveries, which are available for partnering....
Start up announcement
Welcome to ENB Therapeutics. We believe that there are serious deficits in current melanoma therapies. It is our goal to offer better and more cost effective solutions for a devastating disease.